Vanda Pharmaceuticals (VNDA) Share-based Compensation (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Share-based Compensation of $915000.0 for Q1 2025, up 113.93% sequentially from -$6.6 million in Q3 2024, and down 74.47% YoY from $3.6 million in Q1 2024.
Vanda Pharmaceuticals (VNDA) Share-based Compensation (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Share-based Compensation for 16 years, with the latest figure at $915000.0 in Q1 2025.
- Quarterly Share-based Compensation fell 74.47% year-over-year to $915000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $915000.0 (changed N/A YoY) and the FY2025 annual result came in at $915000.0, changed N/A from the prior year.
- Share-based Compensation rose to $915000.0 in Q1 2025 per VNDA's latest filing, from -$6.6 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $4.8 million in Q1 2022 and troughed at -$10.8 million in Q4 2023.
- A 5-year average of $2.0 million and a median of $3.8 million in 2021 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2021 and 2023: Share-based Compensation rose 26.03% in 2021, then slumped 384.62% in 2023.
- Over 5 years, Share-based Compensation stood at $3.8 million in 2021, then increased by 0.24% to $3.8 million in 2022, then plunged by 384.62% to -$10.8 million in 2023, then soared by 38.98% to -$6.6 million in 2024, then surged by 113.93% to $915000.0 in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $915000.0, -$6.6 million, and $3.0 million for Q1 2025, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | 2.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.11 Mn |
| Jun 30, 2026 | 2.11 Mn |
| Mar 31, 2026 | 2.56 Mn |
| Mar 31, 2026 | 2.56 Mn |
| Dec 31, 2025 | 2.29 Mn |
| Dec 31, 2025 | 2.29 Mn |
| Sep 30, 2025 | 2.11 Mn |
| Sep 30, 2025 | 2.11 Mn |
| Jun 30, 2025 | 2.11 Mn |
| Jun 30, 2025 | 2.11 Mn |
| Mar 31, 2025 | 915,000.00 |
| Mar 31, 2025 | 915,000.00 |
| Sep 30, 2024 | -6.57 Mn |
| Sep 30, 2024 | -6.57 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Mar 31, 2024 | 3.58 Mn |
| Mar 31, 2024 | 3.58 Mn |
| Dec 31, 2023 | -10.77 Mn |
| Dec 31, 2023 | -10.77 Mn |